Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) has shared an update.
Aurobindo Pharma has announced that its trading window for dealing in the company’s securities will be closed for all designated persons, including promoters, directors, key managerial personnel, employees, connected persons and their immediate relatives, from 1 January 2026 until 48 hours after the announcement of its unaudited financial results for the third quarter and nine‑month period ending 31 December 2025. The move is in line with SEBI’s insider trading regulations and the company’s internal code of conduct, underscoring its compliance framework and signaling that the timing of forthcoming financial disclosures will temporarily restrict trading activity by insiders until the results are formally released and absorbed by the market; the exact board meeting date for approving these results will be communicated later.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of generic pharmaceuticals and active pharmaceutical ingredients. The company serves both domestic and international markets with a broad portfolio across key therapeutic segments, and its shares are listed on the National Stock Exchange of India and BSE Limited.
Average Trading Volume: 35,507
Technical Sentiment Signal: Strong Buy
Current Market Cap: 711.3B INR
For an in-depth examination of AUROPHARMA stock, go to TipRanks’ Overview page.